The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Teles-Reis J, Rusten TE(2026) Tumour-host interactions in Drosophila: mechanisms in the tumour micro- and macroenvironment Mol Oncol(in press) DOI 10.1002/1878-0261.70207, PubMed 41546533
Zhang X, Johannessen B, Kidd SG, Bogaard M, Stranger A, Axcrona U, Axcrona K, Skotheim RI(2026) Cell type composition in bulk prostate cancer tissue is a prognostic biomarker Neoplasia, 72, 101272(in press) DOI 10.1016/j.neo.2026.101272, PubMed 41534468
Choudhury SR, Gupta I, Mills I, Mukhina V, Loginov A, Allor E, Anderson A, Cellini A, Robles C, Dyalram D, Lubek J, Wolf J, Taylor R, Hatten K, Vorobyeva N, Gaykalova DA(2026) HOXC6 overexpression stimulates cell migration and correlates with poor prognosis in head and neck squamous cell carcinoma Cell Mol Life Sci(in press) DOI 10.1007/s00018-025-06039-3, PubMed 41521225
Teles-Reis J, Rusten TE(2026) Tumour-host interactions in Drosophila: mechanisms in the tumour micro- and macroenvironment Mol Oncol(in press) DOI 10.1002/1878-0261.70207, PubMed 41546533
Ianevski A, Nader K, Nguyen J, Sorger H, Timonen S, Julia E, Pölöske D, Spirk K, Wagner C, Jungherz D, Nakano M, Kadambat Nair S, Ianevski P, Kankainen M, Dias D, Cichońska A, Pemovska T, Pirker C, Berger W, Braun T, Moriggl R, Bachy E, Mustjoki S, Herling M, Neubauer HAet al.(2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery Cancer Res, 86(2), 295-309 DOI 10.1158/0008-5472.CAN-25-0881, PubMed 41166698
Moura DS, Lopez-Marti J, Tawbi H, Keung E, Wani K, Lazar A, Wang WL, Ingram DR, Meza-Zepeda LA, Myklebost O, Burgess M, Mondaza-Hernandez JL, Hindi N, Martín-Broto J(2026) Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS) Clin Cancer Res(in press) DOI 10.1158/1078-0432.CCR-25-2580, PubMed 41537707